Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant, NEJM

Phase 2a –b trial in South Africa (n=4387) found the NVX-CoV2373 vaccine was efficacious in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative patients (60.1%) and of 41 sequenced isolates, 38 (92.7%) were the B.1.351 variant.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news